Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 16/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.56 |
| ▸ | AQP1 | P29972 | 2/20 | 0.52 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | NPY1R | P25929 | 1/20 | 0.51 |
| ▸ | NPY2R | P49146 | 1/20 | 0.51 |
| ▸ | NPY4R | P50391 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13795882 | 0.96 | NPY5R (0.58) | NPY5RSLC6A4AQP1SOS1ADRA2A | |
| SCHEMBL13796366 | 0.93 | NPY5R (0.55) | NPY5RSLC6A4AQP1SOS1ADRA2A | |
| SCHEMBL13795419 | 0.91 | NPY5R (0.68) | NPY5RSLC6A4AQP1SOS1ADRA2A | |
| SCHEMBL13795839 | 0.90 | NPY5R (0.71) | NPY5RSLC6A4AQP1SOS1ADRA2A | |
| SCHEMBL13796365 | 0.90 | NPY5R (0.54) | NPY5RSLC6A4AQP1SOS1ADRA2A | |
| SCHEMBL13795455 | 0.90 | NPY5R (0.57) | NPY5RSLC6A4AQP1SOS1ADRA2A | |
| SCHEMBL13796848 | 0.90 | NPY5R (0.63) | NPY5RSLC6A4AQP1SOS1ADRA2A | |
| SCHEMBL13796991 | 0.90 | NPY5R (0.59) | NPY5RSLC6A4AQP1SOS1ADRA2A | |
| SCHEMBL13796852 | 0.90 | NPY5R (0.66) | NPY5RSLC6A4AQP1SOS1ADRA2A | |
| SCHEMBL13796948 | 0.89 | NPY5R (0.57) | NPY5RSLC6A4AQP1SOS1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544690-B2 | MCH receptor antagonists | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-7544690-B2 | MCH receptor antagonists | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-20070037836-A1 | Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037836-A1 | Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide | MCHR1, MCHR2, MC4R | NPY5R 11/4885SLC6A4 73/4885AQP1 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.